Physician profile
Anna Postolova
NPI 1932475316
$3,452.74
in general payments reported to CMS, 2019-2025
12 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $117 · 2021: $12.75 · 2022: $50.00 · 2023: $130 · 2024: $159 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $435 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $435.03 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progentec Diagnostics, INC. | $2,400.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $291.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $274.54 | 2019-2024 | Benlysta |
| Amgen INC. | $242.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $82.45 | 2019-2024 | Airsupra |
| Gilead Sciences, INC. | $50.00 | 2022 | |
| Kaleo, INC. | $21.63 | 2019 | |
| Genentech USA, INC. | $21.36 | 2024 | Xolair |
| Pharming Healthcare, INC. | $20.37 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.02 | 2019 | |
| Csl Behring | $16.96 | 2025 | Andembry |
| Pfizer INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Postolova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.